Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12749049 | 0.92 | ALDH1A1 (0.60) | CCR2CYP19A1P2RX4KDM4EALDH1A1 | |
| SCHEMBL8506509 | 0.88 | SMN1; SMN2 (0.58) | CCR2CYP19A1P2RX4FOLH1KDM4E | |
| SCHEMBL14584016 | 0.85 | ALDH1A1 (0.61) | CCR2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL14584015 | 0.85 | ALDH1A1 (0.54) | CCR2CYP19A1FOLH1KDM4EALDH1A1 | |
| SCHEMBL612585 | 0.83 | POLB (0.62) | CCR2CYP19A1P2RX4KDM4EALDH1A1 | |
| SCHEMBL28158573 | 0.81 | P2RX4 (0.60) | CCR2CYP19A1P2RX4KDM4EALDH1A1 | |
| SCHEMBL12749039 | 0.81 | LMNA (0.58) | CCR2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL22499375 | 0.81 | CYP19A1 (0.46) | CCR2CYP19A1P2RX4FOLH1KDM4E | |
| SCHEMBL14584017 | 0.81 | CCR2 (0.53) | CCR2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL28115275 | 0.79 | LMNA (0.57) | CCR2KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574787-B | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity | UNIV SINGAPORE | 2014-12-31 | — | — | CN | disclosed |
| US-8742100-B2 | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2014-06-03 | — | — | US | disclosed |
| US-20120197014-A1 | SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2012-08-02 | — | — | US | disclosed |
| CN-102574787-A | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity | UNIV SINGAPORE | 2012-07-11 | — | — | CN | disclosed |
| EP-2459533-A1 | SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY | National University of Singapore (SG) | 2012-06-06 | — | — | EP | disclosed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043057-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015771-A1 | Lonidamine analogs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197014-A1 | SMALL MOLECULE INHIBITORS OF ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE WITH POTENTIAL ANTICANCER ACTIVITY | ICMT, BHMT, SHMT1 | CCR2 3883/4885CYP19A1 3455/4885P2RX4 4812/4885 |
| US-20070015771-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | CCR2 2500/4885CYP19A1 1915/4885P2RX4 4039/4885 |
| US-20070043057-A1 | Lonidamine analogs | LONP1, LPXN, QDPR | CCR2 2500/4885CYP19A1 1915/4885P2RX4 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.